WO2023149549A1 - Nouvelle composition pharmaceutique - Google Patents

Nouvelle composition pharmaceutique Download PDF

Info

Publication number
WO2023149549A1
WO2023149549A1 PCT/JP2023/003581 JP2023003581W WO2023149549A1 WO 2023149549 A1 WO2023149549 A1 WO 2023149549A1 JP 2023003581 W JP2023003581 W JP 2023003581W WO 2023149549 A1 WO2023149549 A1 WO 2023149549A1
Authority
WO
WIPO (PCT)
Prior art keywords
carbon atoms
pharmaceutical composition
cancer
compound
hydroxy
Prior art date
Application number
PCT/JP2023/003581
Other languages
English (en)
Japanese (ja)
Inventor
スレス アワレ
尚樹 豊岡
Original Assignee
国立大学法人富山大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 国立大学法人富山大学 filed Critical 国立大学法人富山大学
Publication of WO2023149549A1 publication Critical patent/WO2023149549A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83—Oxygen atoms

Abstract

Un but de la présente invention est de fournir une nouvelle composition pharmaceutique, en particulier une nouvelle composition pharmaceutique anticancéreuse, et un nouveau composé utilisé pour l'agent anticancéreux.　La présente invention concerne une composition pharmaceutique comprenant, en tant que principe actif, un composé représenté par la formule (I) ci-dessous ou un sel pharmacologiquement acceptable de celui-ci.
PCT/JP2023/003581 2022-02-03 2023-02-03 Nouvelle composition pharmaceutique WO2023149549A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022015849 2022-02-03
JP2022-015849 2022-02-03

Publications (1)

Publication Number Publication Date
WO2023149549A1 true WO2023149549A1 (fr) 2023-08-10

Family

ID=87552624

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2023/003581 WO2023149549A1 (fr) 2022-02-03 2023-02-03 Nouvelle composition pharmaceutique

Country Status (1)

Country Link
WO (1) WO2023149549A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002514636A (ja) * 1998-05-12 2002-05-21 アメリカン・ホーム・プロダクツ・コーポレイション インスリン抵抗性または高血糖症の治療に有用なフェニルオキソ−酢酸類
CN102718735A (zh) * 2012-05-28 2012-10-10 沈阳药科大学 2-乙基-3-（4-羟基）苯甲酰基苯并呋喃类化合物、组合物及其制备方法
JP2013539757A (ja) * 2010-10-06 2013-10-28 ジェイファーマ株式会社 強力な尿酸トランスポーター阻害剤の開発：それらの尿酸排泄効果のために設計された化合物
US20140128460A1 (en) * 2012-03-29 2014-05-08 Children's Hospital Medical Center Use of small molecule inhibitors targeting eya tyrosine phosphatase
JP2019524747A (ja) * 2016-07-18 2019-09-05 アースローシ セラピューティクス，インク． 痛風または高尿酸血症に関連する症状を処置または予防するための化合物、組成物、および方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002514636A (ja) * 1998-05-12 2002-05-21 アメリカン・ホーム・プロダクツ・コーポレイション インスリン抵抗性または高血糖症の治療に有用なフェニルオキソ−酢酸類
JP2013539757A (ja) * 2010-10-06 2013-10-28 ジェイファーマ株式会社 強力な尿酸トランスポーター阻害剤の開発：それらの尿酸排泄効果のために設計された化合物
US20140128460A1 (en) * 2012-03-29 2014-05-08 Children's Hospital Medical Center Use of small molecule inhibitors targeting eya tyrosine phosphatase
CN102718735A (zh) * 2012-05-28 2012-10-10 沈阳药科大学 2-乙基-3-（4-羟基）苯甲酰基苯并呋喃类化合物、组合物及其制备方法
JP2019524747A (ja) * 2016-07-18 2019-09-05 アースローシ セラピューティクス，インク． 痛風または高尿酸血症に関連する症状を処置または予防するための化合物、組成物、および方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BOGNAR ZITA, FEKETE KATALIN, ANTUS CSENGE, HOCSAK ENIKO, BOGNAR RITA, TAPODI ANTAL, BORONKAI ARPAD, FARKAS NELLI, GALLYAS FERENC, : "Desethylamiodarone—A metabolite of amiodarone—Induces apoptosis on T24 human bladder cancer cells via multiple pathways", PLOS ONE, vol. 12, no. 12, 8 December 2017 (2017-12-08), pages e0189470, XP093083345, DOI: 10.1371/journal.pone.0189470 *

Similar Documents

Publication Publication Date Title
RU2640115C2 (ru) Фармацевтические композиции замещенных хиназолинонов
US9539256B2 (en) Modulators of exchange proteins directly activated by cAMP (EPACS)
CN110072528B (zh) 治疗肿瘤的药物组合物
RU2644635C2 (ru) Системы, способы и составы для лечения рака
US20140275183A1 (en) Agent for reducing side effects of kinase inhibitor
JP5440985B2 (ja) メラノーマの治療
KR20160106211A (ko) 네라티닙을 이용한 유방암의 치료법
MX2010012501A (es) Terapia de combinacion con un alcaloide antitumoral.
EP3429582B1 (fr) Polythérapie pour traiter les maladies prolifératives
EP3429572B1 (fr) Polythérapie pour les maladies prolifératives
WO2023149549A1 (fr) Nouvelle composition pharmaceutique
WO2014047782A1 (fr) Composition pharmaceutique contenant du resvératrol, un dérivé de resvératrol et un inhibiteur bcl-2 et son utilisation
JP2019519573A (ja) がんを処置するための方法
Yang et al. ZL11n is a novel nitric oxide-releasing derivative of farnesylthiosalicylic acid that induces apoptosis in human hepatoma HepG2 cells via MAPK/mitochondrial pathways
JP7311177B2 (ja) Ａ－ＮＯＲ－５αアンドロスタン薬物と抗がん薬物との併用
CN111617081B (zh) 一种取代丁烯酰胺联合mTOR抑制剂的药物组合物及其用途
WO2023149548A1 (fr) Nouvelle composition pharmaceutique
JP2019014685A (ja) 抗がん剤
JP7442820B2 (ja) びまん性胃癌の治療剤
WO2016119646A1 (fr) Promédicament de sunitinib et composition pharmaceutique
TW202327579A (zh) Ｔｅａｄ抑制劑的給藥方案
CN114191557A (zh) Cdk4/6抑制剂联合免疫治疗在制备抗癌药物中的用途
WO2023242103A1 (fr) Nouveaux inhibiteurs de ras
WO2023242101A1 (fr) Nouveaux inhibiteurs de ras
WO2022098808A1 (fr) Agents thérapeutiques pour le traitement du carcinome hépatocellulaire

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23749865

Country of ref document: EP

Kind code of ref document: A1